科瓦克辛(Covaxin,代號為BBV152),是印度的一款針對2019冠状病毒病的灭活疫苗,由巴拉特生物技術公司(英语:Bharat Biotech)和印度醫學研究理事會(英语:Indian Council of Medical Research)合作完成,科瓦克辛已於2021年11月3日獲世衛組織發出緊急使用授權[8]。
2020年5月,印度醫學研究理事會(ICMR)國家病毒學研究所(英语:National Institute of Virology)批准,並提供了用於開發由自己國家發明的2019冠状病毒病疫苗[9][10]。2020年6月,印度藥品管理局(DCGI)批准疫苗進入第一及第二階段的人體臨床測試,並取名為科瓦克辛(Covaxin)[11]。印度醫學研究理事會的第一及第二階段的人體臨床測試中共有十二個地點,並對疫苗進行臨床測試的人進行雙盲和安慰劑對照[12][13][14]。
^Schmall, Emily; Yasir, Sameer. India Approves Oxford-AstraZeneca Covid-19 Vaccine and 1 Other. The New York Times. 2021-01-03 [2021-05-09]. ISSN 0362-4331. (原始内容于2021-01-09) (美国英语).
^ 2.02.1Iran issues permit for emergency use for three other COVID-19 vaccines: Official. IRNA English. 2021-02-17 [2021-05-09]. (原始内容于2021-02-27) (英语).
^ 3.03.1Zimbabwe approves Covaxin, first in Africa to okay India-made Covid-19 vaccine. Hindustan Times. 2021-03-04 [2021-05-09]. (原始内容于2021-03-05) (英语).
^ 4.04.1Rédaction, La. Dr Jagutpal: «Une cargaison de 200 000 vaccins Covaxin débarque demain». lexpress.mu. 2021-03-18 [2021-05-09]. (原始内容于2021-04-21) (法语).
^ 5.05.15.2Sharma, Gopal. Nepal becomes third country to give emergency nod to Indian vaccine COVAXIN. Reuters. 2021-03-19 [2021-05-09]. (原始内容于2021-04-25) (英语).
^Covid-19: India provides 100,000 doses of Covaxin vaccine to Paraguay. Hindustan Times. 2021-03-30 [2021-05-09]. (原始内容于2021-05-04) (英语).
^ 7.07.1Staff, Reuters. Mexico authorizes emergency use of Indian COVID-19 vaccine. Reuters. 2021-04-07 [2021-04-07]. (原始内容于2021-04-07) (英语).
^ICMR teams up with Bharat Biotech to develop Covid-19 vaccine. Livemint. 2020-05-09 [2021-04-02]. (原始内容于2021-05-03) (英语).
^Chakrabarti A. India to develop 'fully indigenous' Covid vaccine as ICMR partners with Bharat Biotech. ThePrint. 2020-05-10 [2021-04-02]. (原始内容于2021-05-03).
^India's First COVID-19 Vaccine Candidate Approved for Human Trials. The New York Times. 2020-06-29 [2021-04-02]. (原始内容于2021-02-13).
^Human clinical trials of potential Covid-19 vaccine 'COVAXIN' started at AIIMS. DD News (Prasar Bharati, Ministry of I & B, Government of India). 2020-07-25 [2021-04-02]. (原始内容于2021-01-24).
^Press, Associated. Asia Today: Amid new surge, India tests potential vaccine. Washington Post. 2020-07-25 [2020-12-17]. (原始内容于2021-02-16).
^Delhi: 30-year-old is first to get dose of trial drug Covaxin. The Indian Express. 2020-07-25 [2021-04-02]. (原始内容于2021-03-16) (英语).
^Perappadan, Bindu Shajan. Coronavirus | Covaxin phase-1 trial results show promising results. The Hindu. 2020-12-16 [2020-12-17]. (原始内容于2020-12-17) (英语).
^Ella, Raches; Vadrevu, Krishna Mohan; Jogdand, Harsh; Prasad, Sai; Reddy, Siddharth; Sarangi, Vamshi; Ganneru, Brunda; Sapkal, Gajanan; Yadav, Pragya. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. The Lancet Infectious Diseases. 2021-05-01, 21 (5): 637–646. ISSN 1473-3099. PMID 33485468. doi:10.1016/S1473-3099(20)30942-7(英语).
^ 18.018.1Ella, Raches; Reddy, Siddharth; Jogdand, Harsh; Sarangi, Vamshi; Ganneru, Brunda; Prasad, Sai; Das, Dipankar; Raju, Dugyala; Praturi, Usha. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. The Lancet Infectious Diseases. 2021-03-08, 0 (0). ISSN 1473-3099. PMID 33705727. doi:10.1016/S1473-3099(21)00070-0(英语).
^Ganneru, Brunda; Jogdand, Harsh; Dharam, Vijaya Kumar; Molugu, Narasimha Reddy; Prasad, Sai D; Vellimudu, Srinivas; Ella, Krishna M; Ravikrishnan, Rajaram; Awasthi, Amit. Evaluation of Safety and Immunogenicity of an Adjuvanted, TH-1 Skewed, Whole Virion InactivatedSARS-CoV-2 Vaccine - BBV152. 2020-09-09. doi:10.1101/2020.09.09.285445(英语).
^Coronavirus | Covaxin Phase III trial from November. The Hindu. 2020-10-23 [2021-04-02]. (原始内容于2021-01-26) (英语).
^An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult Volunteers. clinicaltrials.gov (Registry). United States National Library of Medicine. [2020-11-26]. NCT04641481. (原始内容于2020-11-26).
^Bharat Biotech begins Covaxin Phase III trials. The Indian Express. 2020-11-18 [2021-04-02]. (原始内容于2021-01-22) (英语).
^Sen M. List of states that have started phase 3 trials of India's first Covid vaccine. mint. 2020-12-02 [2021-04-02]. (原始内容于2021-02-13) (英语).
^70%-80% Drop In Participation For Phase 3 Trials Of Covaxin: Official. NDTV. 2020-12-17 [2021-04-02]. (原始内容于2020-12-17).
^Bharat Biotech's Covaxin given conditional nod based on incomplete Phase 3 trial results data. The Print. 2021-01-03 [2021-04-02]. (原始内容于2021-03-01).
^Kumar, N. Ravi. Bharat Biotech says COVID-19 vaccine Covaxin shows 81% efficacy in Phase 3 clinical trials. The Hindu. 2021-03-03 [2021-04-02]. (原始内容于2021-04-16) (英语).
^Corum, Jonathan; Zimmer, Carl. Inside the B.1.1.7 Coronavirus Variant. The New York Times. 2021-01-18 [2021-05-09]. ISSN 0362-4331. (原始内容于2021-01-20) (美国英语).
^Sapkal, Gajanan N.; Yadav, Pragya D.; Ella, Raches; Deshpande, Gururaj R.; Sahay, Rima R.; Gupta, Nivedita; Mohan, V Krishna; Abraham, Priya; Panda, Samiran. Neutralization of UK-variant VUI-202012/01 with COVAXIN vaccinated human serum. 2021-01-26. doi:10.1101/2021.01.26.426986(英语).
^Hoeksema, F.; Karpilow, J.; Luitjens, A.; Lagerwerf, F.; Havenga, M.; Groothuizen, M.; Gillissen, G.; Lemckert, A.A.C.; Jiang, B. Enhancing viral vaccine production using engineered knockout vero cell lines – A second look. Vaccine. 2018-04-XX, 36 (16): 2093–2103. PMC 5890396. PMID 29555218. doi:10.1016/j.vaccine.2018.03.010(英语).请检查|date=中的日期值 (帮助) 引文格式1维护:PMC格式 (link)
^Coronavirus vaccine update: Bharat Biotech's Covaxin launch likely in Q2 of 2021, no word on pricing yet. www.businesstoday.in. India Today Group. [2020-12-13]. (原始内容于2020-12-11).
^Odisha fast tracks coronavirus vaccine manufacturing unit. The New Indian Express. 2020-11-07 [2021-04-03]. (原始内容于2021-01-22).
^Raghavan P. Bharat Biotech exploring global tie-ups for Covaxin manufacturing. The Indian Express. 2020-09-24 [2021-04-03]. (原始内容于2021-01-22) (英语).
^Reuters Staff. Ocugen to co-develop Bharat Biotech's COVID-19 vaccine candidate for U.S.. Reuters. 2020-12-22 [2021-01-05]. (原始内容于2020-12-26) (英语).
^Bharat Biotech, Ocugen to co-develop Covaxin for US market. The Economic Times. [2021-01-05]. (原始内容于2021-07-05).
^Bharat Biotech inks pact with Precisa Med to supply Covaxin to Brazil. mint. 2021-01-12 [2021-04-03]. (原始内容于2021-03-29) (英语).
^Ghosh N. Bharat Biotech seeks emergency use authorization for Covid-19 vaccine. Hindustan Times. 2020-12-07 [2021-04-07]. (原始内容于2020-12-24) (英语).
^Coronavirus | After SII, Bharat Biotech seeks DCGI approval for Covaxin. The Hindu. 2020-12-07 [2021-04-07]. (原始内容于2020-12-24) (英语).
^Expert panel recommends granting approval for restricted emergency use of Bharat Biotech's Covaxin. The Indian Express. 2021-01-02 [2021-04-07]. (原始内容于2021-01-26) (英语).
^Coronavirus: India approves vaccines from Bharat Biotech and Oxford/AstraZeneca. BBC News. 2021-01-03 [2021-01-03]. (原始内容于2021-01-03) (英国英语).
^Disputes Mount, but Heedless Govt Intent on Rolling Vaccine Candidates Out. The Wire. 2021-01-12 [2021-04-07]. (原始内容于2021-01-28).
^AIPSN urges govt to reconsider emergency approval for Covaxin till Phase 3 data is published - Health News , Firstpost. Firstpost. 2021-01-08 [2021-04-07]. (原始内容于2021-04-16).